On Oct. 26, biotech company Celgene (NASDAQ:CELG) released third-quarter earnings for the period ended Sept. 30.

  • Revenues and earnings per share were up significantly over last year.
  • Revenues rose by 89% to $245 million on account of strong sales of Revlimid and Thalomid.
  • GAAP net income increased to $20 million due to higher sales.

(Figures in millions, except per-share data)

Income Statement Highlights

Avg. Est.

Q3 2006

Q3 2005

Change

Sales

$228

$244.8

$129.5

89.0%

Net Profit*

--

$20.4

$0.7

2,814.3%

EPS

$0.14

$0.05

$0.00

0%

Diluted Shares

--

404.9

359.7

12.6%

*Net profit does not include income from discontinued operations

Get back to basics with a look at the income statement.

Margin Checkup

Q3 2006

Q3 2005

Change*

Gross Margin

86.03%

79.63%

16.40

Operating Margin

22.17%

7.74%

14.43

Net Margin

8.35%

0%

8.35

*Expressed in percentage points

Margins are the earnings engine. See how they work.

Balance Sheet Highlights

Assets

Q3 2006

Q3 2005

Change

Cash + ST Invest.

$872.5

$746

17.0%

Accounts Rec.

N/A

$61.6

 N/A

Inventory

N/A

$31.7

 N/A


Liabilities

Q3 2006

Q3 2005

Change

Accounts Payable

N/A

$27.0

 N/A

Long-Term Debt

$400

$400

(0.0%)



Learn the ways of the balance sheet.

Cash Flow Highlights

This information wasn't available in the press release.

Find out why Fools always follow the money.

Related companies:

  • Biogen Idec (NASDAQ:BIIB)
  • Amgen (NASDAQ:AMGN)
  • OSI Pharmaceuticals (NASDAQ:OSIP)
  • Genzyme (NASDAQ:GENZ)
  • ImClone Systems (NASDAQ:IMCL)

Related Foolishness:

Biogen Idec is a Motley Fool Stock Advisor selection.For a fun new way to do research on stocks, check out CAPS, the Fool's new investment community.

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.